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Aims Homozygosity for a four-missense single-nucleotide polymorphism haplotype of the human BPIFB4 gene is enriched
in long-living individuals. Delivery of this longevity-associated variant (LAV) improved revascularisation and reduced
endothelial dysfunction and atherosclerosis in mice through a mechanism involving the stromal cell-derived factor-1
(SDF-1). Here, we investigated if delivery of the LAV-BPIFB4 gene may attenuate the progression of diabetic
cardiomyopathy.
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Methods
and results
Compared with age-matched lean controls, diabetic db/db mice showed altered echocardiographic indices of diastolic
and systolic function and histological evidence of microvascular rarefaction, lipid accumulation, and fibrosis in the
myocardium. All these alterations, as well as endothelial dysfunction, were prevented by systemic LAV-BPIFB4 gene
therapy using an adeno-associated viral vector serotype 9 (AAV9). In contrast, AAV9 wild-type-BPIFB4 exerted no
benefit. Interestingly, LAV-BPIFB4-treated mice showed increased SDF-1 levels in peripheral blood and myocardium
and up-regulation of the cardiac myosin heavy chain isoform alpha, a contractile protein that was reduced in diabetic
hearts. SDF-1 up-regulation was instrumental to LAV-BPIFB4-induced benefit as both haemodynamic and structural
improvements were inhibited by an orally active antagonist of the SDF-1 CXCR4 receptor.
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Conclusions In mice with type-2 diabetes, LAV-BPIFB4 gene therapy promotes an advantageous remodelling of the heart, allowing it
to better withstand diabetes-induced stress. These results support the viability of transferring healthy characteristics
of longevity to attenuate diabetic cardiac disease.
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Introduction
Diabetic cardiomyopathy has a complex pathogenic basis and
is therefore difficult to treat by targeting a single candidate
mechanism.1,2 The genetics of healthy longevity may inspire novel
treatments for this condition. Long-living individuals are protected
from the consequences of age-related pathologies. Moreover, their
offspring show a lower incidence of cardiovascular disease, suggest-
ing the healthy phenotype can be transmitted vertically through
generations.3 We postulate that horizontal transfer of genes asso-
ciated with healthy longevity may be a novel way to fight cardiovas-
cular complications in people with diabetes.
Genome-wide association studies have led to the discovery
of polymorphic gene variants linked to exceptional longevity.4
One such study revealed that a four-missense single-nucleotide
polymorphism variant of the bactericidal/permeability-increasing
fold-containing family B member 4 (BPIFB4) associates with extraor-
dinarily prolonged life-span in three different geographic areas.5
Longevity-associated variant (LAV)-BPIFB4 has an allele frequency
of 29.5%, while the wild-type isoform (WT-BPIFB4) allele frequency
is around 66% in the Caucasian population. The prevalence of LAV
homozygosity is 14% in centenarians and 10% in controls.6
BPIFB4 is a secreted protein, its levels are increased in serum
of long-living individuals, and high BPIFB4 levels classify their health
status.7 Likewise, homozygous LAV carriers have higher circulat-
ing BPIFB4 levels and increased phosphorylated endothelial nitric
oxide synthase (eNOS) in circulating mononuclear cells.6,7 Thus,
enhanced qualities and increased circulating quantities may account
for the benefit of carrying the LAV rather than the WT gene.
Systemic delivery of WT-BPIFB4 or LAV-BPIFB4 using
an adeno-associated viral vector (AAV) induced similar
over-expression of the human protein in most tissues of
transfected mice, except for an increase of the LAV protein
in peripheral blood and circulating monocytes. Importantly,
LAV-BPIFB4, but not WT-BPIFB4, protected from hypertension,
ischaemia and atherosclerosis.5,8 Investigation of mechanisms
behind this remarkable superiority indicated that LAV-BPIFB4 is
(i) more efficiently phosphorylated/activated by protein kinase
R-like endoplasmic reticulum kinase and protein kinase C alpha,
(ii) activates a feedforward mechanism that involves increased
calcium mobilisation, and (iii) has greater capacity in binding
14–3-3, recruiting heat shock protein 90, and eventually activating
eNOS.9 Additionally, the anti-atherosclerosis action of LAV-BPIFB4
gene therapy was attributed to a mechanism involving the stromal
cell-derived factor-1 (SDF-1) and related CXCR4 receptor.8
The present study investigates the potential of LAV-BPIFB4 gene
therapy and participation of SDF-1/CXCR4 axis in halting the
progression of diabetic cardiomyopathy.
Methods
Adeno-associated viral vector production
The vector was produced as described previously.5 For each viral
preparation, physical titres (GC/mL) were determined through
dot-blot analysis and polymerase chain reaction quantification using



















































































.. Studies on human cardiac tissue
The study was approved by the Ethics Committee of the University
Hospital of Udine, Italy (number 47831) in accordance with the
Declaration of Helsinki.
BPIFB4 expression was assessed in hearts explanted from patients
undergoing transplantation for ischaemic heart failure. Hearts of
patients that died for causes other than cardiovascular disease
or donated hearts not employed for transplantation were used
as controls (online supplementary Table S1). Formalin-fixed and
paraffin-embedded tissues were cut into 5 μm thick sections and
stained for BPIFB4, CD34 and 𝛼-sarcomeric actin (online supple-
mentary Table S2). Images were acquired with a Leica DMI6000B
microscope (Leica Microsystems, Wetzlar, Germany) and processed
using ImageJ software (https://imagej.net/ImageJ).
Protocols in mice
Experimental procedures were approved by the British Home Office
(PPL numbers 30/2811 and 30/3373), the University of Bristol, the
IRCCS Neuromed Animal Care Review Board, and the Istituto Supe-
riore di Sanità, Rome (1163/2015- PR), and were compliant with the
EU Directive 2010/63/EU and principles stated in the Guide for the
Care and Use of Laboratory Animals (Institute of Laboratory Animal
Resources, 1996). Mice were housed in groups of 3–6 animals or indi-
vidually (as required by the experimental procedure) in an enriched
environment within a bio-secure unit under a 12 h light/dark cycle, fed
with EURodent Diet (5LF5, LabDiet, Durham, UK) and given drinking
water ad libitum.
Ex vivo transfection of mouse vessels
Second-order branches of the mesenteric artery were transfected with
plasmid vector as described.5,8 Vessels were placed in a Mulvany pres-
sure system filled with Krebs solution supplemented with 20 μg of
the pRK5 vector encoding either empty, WT- or LAV-BPIFB4 gene.
Endothelium-dependent and independent relaxation was assessed by
measuring the dilatory responses to cumulative acetylcholine con-
centrations (from 10−9 M to 10−5 M) in vessels pre-contracted with
U46619 at a dose necessary to obtain a similar level of pre-contraction
(80% of initial KCl-evoked contraction) and reported as a percentage
of diameter change. Responses were tested before and after transfec-
tion, in presence or absence of high glucose concentration (25 mM for
1 h), and pre-treatment with the SDF-1 antagonist AMD3100 (1 μM)
or vehicle for 30 min.
In vivo studies
• Study 1: Effect of LAV-BPIFB4 gene transfer on cardiac function of
non-diabetic mice. Nine-week-old male C57BL/6J mice (Charles
River, Margate, Kent, UK) under isoflurane anaesthesia received
100 μL of 1 × 1012 GC/mL AAV9-LAV-BPIFB4 or vehicle (PBS) (n = 6
per group) via the tail vein. Four weeks later, animals underwent
echocardiography under general anaesthesia, followed by termina-
tion for tissue harvesting.
• Study 2: Comparison of the effect of a single intravenous injec-
tion of AAV9-LAV- or WT-BPIFB4 in type 2 diabetic mice. One
week after baseline echocardiography, 9-week-old male
C57BLKS/J-Leprdb/Leprdb/Dock7+ [db/db] mice (Envigo, Bicester,
Oxfordshire, UK) were intravenously injected, under isoflu-
rane anaesthesia, with either AAV9-LAV-BPIFB4, AAV9-WT-BPIFB4
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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(100 μL at 1 × 1012 GC/mL) or vehicle (PBS). Each treatment
group consisted of 8 mice. Age-matched lean non-diabetic mice
[C57BLKS/J-Leprdb/LeprWT Dock7+ (wt/db), Envigo] were
used as controls (n = 8). Four weeks later, mice underwent
a final echocardiography followed by blood and tissue collec-
tion for molecular and histological analyses. Using the same
randomisation protocol, mice underwent a cardiac positron
emission tomography/computed tomography (PET/CT) scan
under terminal anaesthesia to assess the myocardial uptake of
2-deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG).
An additional cohort of singly-housed 28 diabetic mice was ran-
domised to receive AAV9-LAV-BPIFB4 or AAV9-GFP (100 μL at 1 × 1012
GC/mL) control virus through the tail vein in association with
2 mg/kg/day AMD-070 (Generon, UK), a specific CXCR4 antagonist, or
DMSO (vehicle) orally in sugar-free jelly. Mice were conditioned to eat
the jelly for 1 week before entering the study; the jelly was given daily
and intake was monitored closely throughout the study. Four weeks
later, mice were sacrificed after a terminal echocardiography.
• Study 3: Effect of AAV9-LAV-BPIFB4 gene therapy on systemic blood
pressure and endothelial function. Nine-week-old male db/db
and wt/db mice (Envigo) were randomly attributed to receive
AAV9-LAV-BPIFB4 (100 μL at 1 × 1012 GC/mL) or AAV9-GFP control
virus (100 μL at 1 × 1012 GC/mL) (n = 5 per group) through
the tail vein. Blood pressure was monitored using tail-cuff
plethysmography.10 Four weeks post-treatment, mesenteric
arteries were excised for assessment of vascular reactivity and
molecular analyses.11 Vasorelaxation was evaluated using increas-





Dimensional and functional parameters were measured by two inde-
pendent investigators (Z.D. and A.C.T.) using a Vevo-3100 echocardio-
graphy system (Fujifilm VisualSonics Inc, Toronto, Canada) and MX400
or MX550D transducers according to the animal size.12,13 The study
was performed with mice under isoflurane anaesthesia (2.5% for induc-
tion, followed by 0.5–1.2% as appropriate to maintain heart rate close
to 450 bpm.
Positron emission tomography/computed tomography
imaging
The study was conducted at PETIC, Cardiff University, UK, using a
Mediso nanoScan 122S small bore PET/CT imaging system (Mediso
Medical Imaging Systems, Budapest, Hungary). The protocol was stan-
dardised to ensure optimal and consistent biodistribution of 18F-FDG.
Briefly, mice had food withdrawn and were warmed at 37∘C 1 h
before scanning, which was done under isoflurane-anaesthesia (∼2%
in 1 L/min oxygen). An intraperitoneal injection of 100–150 μL of
Iohexol CT contrast agent (647 mg/mL) (Omnipaque 300, GE Health-
care Inc., Marlborough, MA, USA) was followed by a tail vein injection
of 32± 8 MBq 18F-FDG. A 20-min cardiac gated PET scan was acquired
followed by a 2.5 min whole-body CT scan. Cardiac 18F-FDG uptake




















































































Peripheral blood levels of C-peptide and insulin were assessed using
a Mouse Milliplex kit (MMHMAG-44 K, Millipore, Burlington, MA,
USA), atrial natriuretic peptide (ANP) was determined using EIA
(RAB00385, Sigma-Aldrich), and SDF-1 was measured using an ELISA
kit (CXCL12/SDF-1 Quantikine ELISA Kit, DY350-05, R&D Sys-
tems). BPIFB4 protein levels were determined using an ELISA kit
(CSB-EL003694HU, Cusabio Technology, Houston, TX, USA). Accord-
ing to the vendor, the ELISA has an excellent specificity for the
human protein, but cross-reaction with the mouse protein cannot be
excluded.
Histological analyses of mouse hearts
Sections were stained with specific antibodies employing the proce-
dures listed in online supplementary Table S2 and analysed using optical
or fluorescence microscopy. Dimensional measures of nucleated car-
diomyocytes were acquired using morphometry. Cardiomyocyte length
and transversal diameter were analysed on 𝛼-sarcomeric actin stained
tissue sections, in fields where cells were perfectly longitudinal, showed
nuclei centered in the cell body and intercalated discs were apparent.
A line crossing the centre of nuclei was drawn and the length of the
segment crossing the opposite intercalated discs was then measured,
in analogy to what has been described in Vliegen et al.,14 and published
by us recently.15
Vascular density was assessed by counting capillaries in at least 10
fields (200x magnification). Final data were expressed as the number
of capillaries per mm2. Quantitative assessment of proliferation and
apoptosis was carried out by counting the total number of Ki67,
phosphorylated-histone H3 and TUNEL-positive cells in two complete
cardiac sections per animal (630x magnification). Myocardial interstitial
and perivascular fibrosis were identified using either Picrosirius Red
or Azan Mallory (Sigma-Aldrich) staining. Neutral lipid droplets were
identified using Oil Red O (ORO) 2% (Sigma-Aldrich) staining. At least
10 random fields were analysed (200x or 400x magnification). Areas of
positive staining were measured in pixels and expressed as a percentage
of total tissue area. Perivascular fibrosis was expressed as previously
described.16 For ORO, measurements were further validated in tissue
extracts measuring the dye concentration at 490 nm.
For quantification of BPIFB4, SDF-1 and myosin heavy chain isoform
𝛼 (MyHC-𝛼) expression, the whole left ventricular area was imaged
and analysed. For BPIFB4, multiple photographs were taken with an
INCell Analyser 2200 microscope (GE Healthcare Inc.) and collated to
re-construct the whole left ventricle.
Molecular analyses
RNA isolation and RT-qPCR
Total RNA was isolated from flash-frozen murine left ventricular
myocardium using TRIzol (Thermo Fisher Scientific, UK). The TaqMan
primer-probes for mouse Bpifb4 and Col1a1 were obtained from
Thermo Fisher Scientific. Analysis was performed using the 2-ΔΔCt
method with results normalised to 𝛽-actin (Actb) internal control gene.
Protein extraction and western blotting
Proteins were extracted in RIPA buffer supplemented with a cocktail
of proteases and phosphatases inhibitors (all from Sigma) and concen-
tration was determined using the BCA Protein Assay Kit (Thermo
Fisher Scientific). Primary antibodies (online supplementary Table S3)
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
4 Z. Dang et al.
were incubated for 16 h at 4∘C. Either 𝛽-actin or 𝛽-tubulin were
used as loading control. Anti-rabbit or -mouse IgG HRP-conjugated
were employed as secondary antibodies (both 1:5000, GE Health-
care). Membrane development was performed by an enhanced
chemiluminescence-based detection method (ECL™ Prime Western
Blotting Detection Reagent, GE Healthcare) in a ChemiDoc-MP sys-
tem (Bio-Rad). No more than one stripping procedure was performed
on an individual membrane (RestoreTM Plus Western Blot Stripping
Buffer, Thermo Fisher Scientific).
Studies on human cells
The study was approved by the Ethics Committee of IRCCS Neuromed
(No. 20160106–1006) and conducted in accordance with the Dec-
laration of Helsinki. All participants gave written informed consent.
Peripheral blood mononuclear cells from diabetic patients were iso-
lated over Ficoll–Hypaque gradients (lymphocyte separation medium;
MP Biomedicals, Aurora, OH, USA).
Flow cytometry detection of stromal cell-derived
factor-1 positive mononuclear cells following exposure
to WT-BPIFB4 or LAV-BPIFB4 protein
For intracellular detection of SDF-1 positive cells, peripheral blood
mononuclear cells were maintained in culture for 48 h in the pres-
ence or absence of either WT- or LAV-BPIFB4 protein (18 ng/mL)
produced as previously described.17 For detection of SDF-1, a pre-
liminary immunostaining of surface lineages markers (CD3, CD14,
CD16, CD19, CD56, CD66) was performed. After 20 min incubation
at 4∘C in the dark, cells were washed and resuspended in PBS for the
intracellular staining using the BD Cytofix/Cytoperm™ Fixation and
Permeabilization Solution (BD Biosciences) according to the manufac-
turer’s instructions. Cells were washed and resuspended in staining
buffer (PBS+ 2% foetal bovine serum). For each experimental condi-
tion, approximately 1*106 cells were analysed using a FACS Verse Flow
Cytometer (BD Biosciences). Antibodies are reported in online sup-
plementary Table S4).
Statistical analysis
Data are shown as individual values and mean± standard error of
the mean, with categorical variables as percentages. Comparisons
were made using the Student’s t-test and one- or two-way analysis
of variance (ANOVA), as appropriate. The Brown–Forsythe test was
used to determine equal variance between groups. Post-hoc analysis of
ANOVA included Tukey and Welch tests, as appropriate.
Results
BPIFB4 expression in the failing human
heart
In human hearts, immunoreactive BPIFB4 was detected in both
cardiomyocytes and endothelial cells (Figure 1). BPIFB4 expression
was reduced in cardiomyocytes of failing hearts, with 13 out 40
(32.5%) samples showing values below the lower limit of the
control group. There was no difference between groups regarding



















































































.. Forced expression of LAV-BPIFB4
in non-diabetic mice
In study 1, we sought to determine if the expression of the
LAV-BPIFB4 transgene can alter normal heart function in young adult
mice (protocol and results shown in online supplementary Figure
S1A and supplementary Table S5). No change in echocardiography
indices was observed in the LAV-BPIFB4-treated group, except an
increase in the diastolic filling index E/A (P = 0.02 vs. vehicle).
Validation of the diabetic murine model
In line with previous studies reviewed,18 db/db mice showed overt
glycosuria [>2000 (110) mg/dL (mmol/L), data not shown] and
excess body weight at 8 to 13 weeks of age (online supplemen-
tary Figure S2A). High levels of C-peptide (P = 0.02 vs. controls)
and insulin (P = 0.0006 vs. controls) were detected in peripheral
blood at termination. Reduced 18F-FDG uptake by the heart (56%,
P = 0.02 vs. controls) confirmed a state of myocardial insulin resis-
tance typical of the model (online supplementary Figure S2B–D).19
Moreover, the CT scan showed a remarkable increase of the sub-
cutaneous fat pad (online supplementary Figure S2D).
Echocardiography validated the detrimental effect of diabetes on
cardiac function (online supplementary Table S6 and Figure S2E–G).
At the 13-week assessment, diastolic abnormalities were illustrated
by a reduction in the E/A ratio (14%, P = 0.009 vs. controls)
and mitral valve deceleration (25%, P = 0.036 vs. controls), and
an increase in deceleration time (22%, P = 0.006 vs. controls).
Fractional shortening (FS) and left ventricular ejection fraction
(LVEF) declined from 8 to 13 weeks (3.8 and 4.1 percentage
points, respectively, P< 0.05 for both comparisons), with both
contractility parameters being depressed in 13-week-old diabetic
mice compared with age-matched controls (FS, 5.9 percentage
points P = 0.004; LVEF, 6.5% points, P = 0.006). Hair re-growth in
the area depilated to perform echocardiography was reduced in
the diabetic group (P< 0.001 vs. controls; online supplementary
Figure S2H).
As shown in online supplementary Figure S3A, cardiomyocytes of
diabetic mice showed a 1.13-fold increase in cross-sectional area
(P = 0.04 vs. controls), but no change in length (P = 0.18; data not
shown). Down-regulation of MyHC-𝛼 may contribute to impaired
cardiac performance in diabetes.20,21 MyHC-𝛼 immunostaining was
reduced by 50% in the heart of diabetic mice (P = 0.04 vs. controls;
online supplementary Figure S3B). Moreover, the ratio between
the MyHC-𝛼 and MyHC-𝛽 isoforms was reduced in the heart of
diabetic mice, as assessed by western blot analysis (P< 0.01 vs.
controls; online supplementary Figure S3C). As shown in online
supplementary Figure S3D–H, diabetes reduced capillary density
(P< 0.0001), while increasing interstitial (P = 0.04) and perivascu-
lar myocardial fibrosis (P< 0.001), collagen, type I, 𝛼1 expression
(P = 0.03), and lipid content (P = 0.002). The staining for BPIFB4
did not differ in the heart of diabetic and control mice (online
supplementary Figure S3I). Similarly, no difference between groups
was observed regarding the ANP protein levels in the heart and
immunoreactive ANP concentration in blood (online supplemen-
tary Figure S3J–K). This is in line with previous publications which
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 BPIFB4 expression in human cardiac samples. Samples were obtained from control hearts (A,E, control) and patients with ischaemic
heart failure (IHF) with diabetes (B,F) or without (C,G). (A–D) BPIFB4 expression in cardiomyocytes. Fluorescence microscopy images show
BPIFB4 in red fluorescence, cardiomyocytes 𝛼-sarcomeric actin in green fluorescence, nuclei in blue (DAPI). (E–H) BPIFB4 expression in
endothelial cells. BPIFB4 is in red fluorescence, CD34+ endothelial cells are shown with cyan pseudocolour, nuclei blue. All scale bars = 10 μm.
The BPIFB4 channel (red) is provided also separately with the microphotographs labelled as (ii) for a better observation of the positive staining.
In (D,H) data indicate the expression of BPIFB4 in cardiomyocytes (D) and endothelial cells (H) calculated as the positive volume fraction
(percent of BPIFB4 positive staining in either cardiomyocytes or endothelial cells). In (D): n = 10 control, 14 diabetic, and 26 non-diabetic.
In (H): n = 10 control, 14 diabetic, and 26 non-diabetic. Data are shown as individual values and mean. *P< 0.05 vs. controls. Red symbols
correspond to carriers of the LAV-BPIFB4 variant.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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show that cardiac ANP is unaltered, or even reduced, in obesity
models like db/db mice,22–24 and that circulating ANP is rapidly
eliminated by clearance receptors in adipocytes.25
BPIFB4 gene therapy in diabetic mice
We next investigated if forced expression of the human BPIFB4 gene
protects the heart from diabetes-induced damage, and if LAV-BPIFB4
is superior to WT-BPIFB4 in this respect (protocol in Figure 2A and
online supplementary Figure S1B).
The liver-specific thyroxine-binding globulin (TBG) promoter
was adopted for the AAV assembling.6 As a confirmation, GFP flu-
orescence was detected in the liver (online supplementary Figure
S4.A–F), but not in the heart (online supplementary Figure S4.G–J),
of mice injected with the AAV-GFP vector. Using an antibody
that recognises both the murine and human protein, we demon-
strated that WT-BPIFB4 and LAV-BPIFB4 gene transfer induced sim-
ilar increases in BPIFB4 staining in the heart, with specific local-
isation of the fluorescent signal in cardiomyocytes (P< 0.01 vs.
vehicle; Figure 2B). Using RT-qPCR and human-specific primers,
validated on human coronary artery endothelial cells (data not
shown), we could not detect any BPIFB4 mRNA transcript in the
heart of mice given gene therapy (either WT-BPIFB4 or LAV-BPIFB4).
Additionally, RT-qPCR with murine-specific primers showed simi-
lar Bpifb4 transcript levels in the heart of vehicle and WT-BPIFB4-
or LAV-BPIFB4-treated groups (online supplementary Figure S5A).
Together, these data suggest that (i) the liver, but not the heart,
was transduced by the viral vector, and (ii) the up-regulation of
BPIFB4 in cardiomyocytes of WT-BPIFB4- or LAV-BPIFB4-treated
mice was likely due to an uptake of circulating protein and not
to an induction of the endogenous murine gene. These data fit
with the increased BPIFB4 protein levels detected in monocytes
of LAV-BPIFB4-treated ApoE knockout mice, without any mRNA
upregulation (either human or murine).8 To verify that the trans-
genic protein was also present in the plasma fraction, we mea-
sured BPIFB4 using a human-dedicated ELISA on samples collected
4 weeks after gene therapy. The assay detected the protein in
plasma of the vehicle group, thus suggesting cross-reactivity of
the antibody for murine Bpifb4. Consequently, the finding that
BPIFB4-transduced mice did not show increased plasma levels com-
pared with vehicle should be considered with caution (online
supplementary Figure S5B).
Neither WT-BPIFB4 nor LAV-BPIFB4 affected body weight
or metabolic control, with both groups showing glycosuria
(>2000 mg/mL), and high C-peptide and insulin levels in peripheral
blood (Figure 2C–E). Moreover, the 18F-FDG uptake by the heart
was similar in all groups (Figure 2F).
Randomised groups were well balanced for basal echocardio-
graphy parameters, whereas there were significant differences
attributable to the treatments (Figure 2H–M and online supple-
mentary Table S6). LAV-BPIFB4 improved diastolic function, pre-
venting the increase in mitral valve deceleration time seen in the
other groups (Figure 2G–I). Dimensional assessment denoted no
effect of treatments on left ventricular mass, whereas LAV-BPIFB4,
but not WT-BPIFB4, prevented the increase in end-systolic vol-



















































































.. LAV-BPIFB4-treated mice showed improved systolic function com-
pared with vehicle or WT-BPIFB4 groups (Figure 2H–M). Both
stroke volume and cardiac output increased in the LAV-BPIFB4
group from baseline to final measurements (17% and 23%, respec-
tively, P< 0.01 for both comparisons). These changes could not
be ascribed to differences in heart rate, which was similar among
groups at baseline and final measurements (online supplementary
Table S6). An accelerated hair re-growth was observed in mice
treated with LAV-BPIFB4 (P< 0.05 vs. vehicle), but not in those given
WT-BPIFB4 (Figure 2N).
Neither WT-BPIFB4 nor LAV-BPIFB4 influenced cardiomyocyte
size (Figure 3A) or apoptosis, as assessed by TUNEL staining (data
not shown). Although Ki67+ cardiomyocytes were more frequent
in the LAV-BPIFB4 group (P< 0.05 vs. vehicle, online supplemen-
tary Figure S6A,B), phosphorylated histone H3 expression was very
rare (online supplementary Figure S6C), thus ruling out an effect
of gene therapy on proliferation. Importantly, LAV-BPIFB4, but not
WT-BPIFB4, increased the expression of MyHC-𝛼 in cardiomy-
ocytes, together with the ratio between the 𝛼 and 𝛽 MyHC iso-
forms in the heart (P< 0.05 vs. vehicle for both comparisons,
Figure 3B,C). In addition, LAV-BPIFB4 gene therapy increased the
density of capillaries, while reducing lipid content, and intersti-
tial and perivascular fibrosis (P< 0.01 vs. vehicle for all compar-
isons; Figure 3D-G). The reduction in fibrosis was likely due to
enhanced collagen degradation, since cardiac Col1a1 mRNA levels
were not affected by LAV-BPIFB4 gene therapy (Figure 3H). Like-
wise, LAV-BPIFB4 did not affect the levels of ANP in the heart and
peripheral blood (Figure 3I,J).
Implication of the SDF-1/CXCR4
in LAV-BPIFB4-induced cardiac
protection
The SDF-1/CXCR4 duo is reportedly involved in LAV-BPIFB4 capac-
ity to induce M2 macrophage polarisation in an atherosclerotic
model.8 New results from flow cytometry analysis of circulating
mononuclear cells from type 2 diabetic patients indicate that in vitro
stimulation with the LAV-BPIFB4 protein selectively induced the
expression of SDF-1 in CD14+CD16+ intermediate monocytes,
but not in other leukocyte populations (Figure 4A–D).
Moreover, we gathered new evidence supporting a role of SDF-1
in LAV-BPIFB4-induced protection against diabetic cardiomyopathy.
LAV-BPIFB4-treated mice had higher levels of circulating SDF-1
compared with the WT-BPIFB4 and vehicle group (P< 0.01 for
both comparisons; Figure 4E). Western blot analysis and immunos-
taining of left ventricular tissue showed that LAV-BPIFB4, but not
WT-BPIFB4, increased SDF-1 expression in the heart of diabetic
mice (Figure 4F–G). Staining of consecutive sections identified the
concurrent upregulation of BPIFB4, SDF-1 and MyHC-𝛼 in car-
diomyocytes of LAV-BPIFB4-treated mice (Figure 4H and online sup-
plementary Figure S7).
To establish a cause–effect relationship, diabetic mice were ran-
domised to receive LAV-BPIFB4 or GFP in combination with the
orally active CXCR4 antagonist, AMD-070, or its vehicle, DMSO
(Figure 5A and online supplementary Figure S1B). Of the 16 mice
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Rescue of diabetic heart by a longevity gene 7
Figure 2 LAV-BPIFB4 gene therapy improves cardiac function in type 2 diabetic mice. (A) Diagram of mice randomisation (n = 8 mice
per group). (B) Immunohistochemistry of BPIFB4 (green fluorescence) in the whole left ventricle (bar 1 mm) and a magnified section (bar
100 μm). Bar graph showing individual values and mean± SEM of positive staining in the three groups. **P< 0.01, ***P< 0.001 vs. the vehicle
group (V). (C) Body weight assessed at 8 and 13 weeks. Individual and mean values. **P< 0.01 vs. 8 weeks. (D–E) Peripheral blood levels
of C-peptide and insulin (mean± SEM). (F) Representative images and bar graph (mean± SEM) of 18F-fluorodeoxyglucose (FDG) positron
emission tomography/computed tomography imaging [values expressed as percent of injected dose (ID) per gram of tissue; n = 3 per group].
(G–M) Graphs showing results of echocardiography assessments at 8 and 13 weeks. Representative images of E and A waves measured using
pulsed-wave Doppler (G) and M-mode traces (H). Graphs showing the improvement induced by AAV-LAV-BPIFB4 (LAV) on indices of diastolic
and systolic function: (I) deceleration time (DT), (J) fractional shortening (FS), (K) stroke volume (SV), (L) left ventricular ejection fraction
(LVEF), (M) cardiac output (CO). Data expressed as individual values and mean± SEM; n = 8 mice per group. *P< 0.05 and **P< 0.01 vs.
vehicle (V), #P< 0.05 and ##P< 0.01 vs. AAV-WT-BPIFB4 (WT), +P< 0.05 and ++P< 0.01 vs. 8 weeks within the same group. (N) The degree
of hair re-growth determined at 13 weeks in the chest area depilated for performing echocardiography. A 9-block grid system was used, with
hair growth within grids scored 1–9, with a further score 9 for mice with complete hair re-growth. Graph showing individual values and
mean± SEM in the three groups. **P< 0.01 vs. vehicle (V) and ##P< 0.01 vs. AAV-WT-BPIFB4 (WT).
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 LAV-BPIFB4 promotes cardiomyocyte expression of contractile protein and prevents capillary rarefaction, lipid accumulation
and fibrosis. (A) Representative fluorescence images showing areas of transversally sectioned myocardium. Cardiomyocytes identified by
𝛼-sarcomeric actin staining (white pseudocolour) and nuclei labelled by DAPI. Scale bars: 50 μm. Right panels are higher magnifications of
the areas delimited by a green outline. Graph shows morphometric data of cardiomyocyte cross-sectional area (CSA) from individual mice
(n = 5 to 6 per group) together with mean± SEM. (B) Representative fluorescence images showing the expression of myosin heavy chain
isoform alpha (MyHC-𝛼). Scale bar: 100 μm. Graph with individual values (n = 6 per group) together with mean± SEM. **P< 0.01 vs. vehicle,
#P< 0.05 vs. WT. (C) Western blot analysis confirming the induction of MyHC-𝛼 and increased ratio between MyHC-𝛼 and MyHC-𝛽 . Individual
values (n = 6 per group) with mean± SEM. *P< 0.05 vs. vehicle, #P< 0.05 vs. WT. (D) Myocardial microvasculature. Representative images of
isolectin B4 (green) positive endothelial cells and 𝛼-smooth muscle actin (red) positive smooth muscle cells, with nuclei identified by DAPI
(blue). Scale bars: 50 μm. Graph showing the relative abundance of capillaries (n = 7 to 10 mice per group). Individual values and mean± SEM.
**P< 0.01 vs. vehicle, ##P< 0.01 vs. WT. (E) Lipid accumulation. Representative images of Oil red O staining and graph showing morphometric
data of lipid accumulation expressed as percentage of the area section. Scale bars: 5 μm. Individual values and mean± SEM. n = 4 to 5 mice per
group. **P< 0.01 vs. vehicle, ##P< 0.01 vs. WT. (F,G) Interstitial (F) and perivascular (G) fibrosis (triangles point to blood vessels). Representative
images of picrosirius red staining and graph showing morphometric data of fibrosis. Scale bars: 50 μm. Individual values and mean± SEM; n = 5
mice per group. *P< 0.05 and **P< 0.01 vs. vehicle, ##P< 0.01 vs. WT. (H) Cardiac Col1a1 mRNA individual values and mean± SEM; n = 6
per group. (I) Western blot of cardiac atrial natriuretic peptide (ANP). Individual values and mean± SEM; n = 6 per group. (J) Immunoreactive
ANP levels in peripheral blood. Individual values and mean± SEM; n = 8 to 10 per group.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 LAV-BPIFB4 induces stromal cell-derived factor-1 (SDF-1) in human monocytes in vitro and in peripheral blood and hearts of diabetic
mice in vivo. (A–D) Cytofluorimetric analysis of the peripheral blood mononuclear cells (PBMCs) from type 2 diabetic patients incubated with
WT-BPIFB4 or LAV-BPIFB4 protein or vehicle for 48 h. LPS was used as a positive control stimulation. At the end of the cell culture treatment,
PBMCs were recovered, stained for the different antigens and anti-intracellular SDF-1, and analysed by flow cytometry. (A) T cells, NK cells,
neutrophils, and B cells. (B) Monocytes. (C) Frequency of SDF-1 positive events within subclasses of monocytes. (D) Relative fluorescence
intensity of SDF-1 in the intermediate monocyte population. Individual values and mean± SEM. n = 4 biological replicates. *P< 0.05. (E)
Immunoreactive SDF-1 levels in murine peripheral blood. Bar graphs show individual values and mean± SEM. n = 11–13 mice per group.
**P< 0.001 between longevity-associated variant (LAV) and other groups. (F) Immunohistochemistry (SDF-1 in green, DAPI in blue, scale bars:
100 μm) and (G) western blot analyses of SDF-1 expression in the mice heart. Bar graphs show individual values and mean± SEM. n = 5–8
mice per group. *P< 0.05, ***P< 0.001 vs. vehicle; #P< 0.05, ###P< 0.001 vs. WT. (H) Immunohistochemistry (scale bars: 100 μm) of BPIFB4,
SDF-1 and myosin heavy chain isoform alpha (MyHC-𝛼) expression (all in green), 𝛼-sarcomeric actin in red, and DAPI blue. Triangles indicate
cardiomyocytes co-expressing the three proteins.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 5 Inhibition of the effects of LAV-BPIFB4 gene therapy by an antagonist of the CXCR4 receptor. (A) Experimental protocol: seven
mice entered the study but only six in each antagonist group were considered because compliant in taking the medicated jelly. All data shown
as individual values and means ± SEM. (B–F) Results of echocardiography. The antagonist inhibits the effect of LAV-BPIFB4 gene therapy on
deceleration time (DT) (B), end-systolic volume (ESV) (C), fractional shortening (FS) (D), left ventricular ejection fraction (LVEF) (E), and cardiac
output (CO) (F). *P< 0.05 and **P< 0.01 vs. GFP+DMSO, #P< 0.05 and ##P< 0.01 in comparison with changes between LAV+DMSO and
GFP+DMSO. (G) Capillary density (scale bars: 50 μm). Isolectin B4 (green) identifies endothelial cells, 𝛼-smooth muscle actin (red), and DAPI
nuclei (blue). Bar graph showing the results. **P< 0.01 vs. GFP+DMSO, ##P< 0.01 in comparison with changes between LAV+DMSO and
GFP+DMSO. (H,I) Cardiac interstitial (H) and perivascular (I) fibrosis (blue) analysed by Azan Mallory staining (scale bars: 50 μm). ***P< 0.001
vs. GFP+DMSO, ##P< 0.01 in comparison with changes between LAV+DMSO and GFP+DMSO.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 6 LAV-BPIFB4 gene therapy benefits vascular function in diabetic mice (study 3). (A) Systolic blood pressure (SBP) in non-diabetic (ND)
mice and obese diabetic mice treated with AAV9-LAV-BPIFB4 or AAV9-GFP (n = 5 to 6 per group). Arrow indicates gene therapy delivery time
point. *P< 0.05 diabetic vs. diabetic given AAV9-GFP; #P< 0.05 ND vs. ND given AAV9-GFP. (B) Heart rate data in the same animals. (C,D) Graphs
show blood glucose levels (C) and body mass (D) before and after treatment with AAV9-LAV-BPIFB4 or AAV9-GFP. *P< 0.05 vs. diabetic given
AAV9-GFP and #P< 0.05 vs. diabetic given AAV9-LAV-BPIFB4. (E–H) Assays performed on mesenteric arteries excised 4 weeks after gene therapy.
(E) Graphs show the dose–response curves to acetylcholine (ACh, 10−9 M to 10−5 M), n = 5 experiments. *P< 0.05 and **P< 0.01 vs. ND
given AAV9-GFP; §P< 0.05 and §§P< 0.01 vs. ND given AAV9-GFP; #P< 0.05 and ##P< 0.01 vs. all. (F) Representative western blot of mesenteric
arteries obtained from ND and diabetic mice treated with AAV9-LAV-BPIFB4 or AAV9-GFP. (G) Bar graphs show optical density quantification.
n = 3 experiments. Individual values and means ± SEM. *P< 0.05. (H) Dose–response curves to nitroglycerine (10−9 M to 10−5 M). n = 5
experiments. All data are given as means ± SEM.
entering the AMD-070 treatment, two (one in the LAV-BPIFB4 and
the other in the GFP group) were excluded because of not tak-
ing the medicated jelly. The effective inhibition of downstream
signalling by AMD-070 was confirmed by assessing the phos-
phorylation/activation of Erk1/2 in the heart (online supplemen-
tary Figure S8A,B). This study provided two important results. First,
it confirmed LAV-BPIFB4 gene therapy improved functional and
structural endpoints in comparison with a control group injected
with the AAV-GFP, thus excluding a background effect of the
viral vector used to transfer the LAV-BPIFB4 sequence. Second,
the CXCR4 antagonist precluded LAV-BPIFB4 benefits on echocar-
diographic, histological, and expressional endpoints (Figure 5 and
online supplementary Table S7). This included the repression of
LAV-BPIFB4-induced increase in MyHC-𝛼 and MyHC-𝛼 to MyHC-𝛽
ratio (online supplementary Figure S8C,D).
LAV-BPIFB4 improves vascular function
in diabetic mice
The protocol assessing systemic haemodynamics and endothe-































.. LAV-BPIFB4 caused a temporary reduction in systolic blood pres-
sure in diabetic and non-diabetic mice, with pressure values return-
ing to baseline by day 6 until the end of the study (Figure 6A).
No treatment effect was observed on heart rate throughout the
study duration (Figure 6B). Plasma glucose levels and body mass
were not different in mice given LAV-BPIFB4 or control viral vector
(Figure 6C,D). Moreover, LAV-BPIFB4 improved the diabetes-induced
impairment in endothelial-dependent vasorelaxation and eNOS
phosphorylation (Figure 6E–G), without affecting vasorelaxation by
nitroglycerine (Figure 6H). Taken together, these results indicate
that although the haemodynamic effect of LAV-BPIFB4 vanished after
1 week, the benefit on endothelial-mediated vasorelaxation per-
sisted up to a month after treatment, which is in line with our
previous report in aged mice.5
Finally, we assessed if vessels transfected with LAV-BPIFB4
are protected from high glucose-induced endothelial dysfunc-
tion through a CXCR4-mediated mechanism. In line with
this, ex vivo LAV-BPIFB4-transfected vessels were responsive to
acetylcholine-evoked vasorelaxation (online supplementary Figure
S9), which was not observed using empty- or WT-BPIFB4-containing
vectors (online supplementary Figure S9). Moreover, treatment
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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with AMD3100, a selective CXCR4 receptor inhibitor, abolished
the benefit of LAV-BPIFB4 on vascular function (online supple-
mentary Figure S9), thus supporting the involvement of CXCR4
signalling.
Discussion
In the present study, ischaemic heart failure was associated with an
increased incidence of BPIFB4 down-regulation in cardiomyocytes
as assessed by immunohistochemistry, with no additional effect
being seen in the diabetic group. LAV-BPIFB4 homozygosity was
detected at the expected frequency, but carriers were too few to
allow associative assessments.
Next, we sought to determine if LAV-BPIFB4 therapy can prevent
the early progression of cardiomyopathy in a model of type 2
diabetes. The study was completed with no loss to follow-up and
no evidence of adverse events. Interestingly, LAV-BPIFB4, but not
WT-BPIFB4, exerted therapeutic effects, despite both appearing to
fail in achieving metabolic control. General inspection denoted an
accelerated hair re-growth in LAV-BPIFB4-treated animals, which
may be compatible with improvements in dermal microangiopathy
and follicle dysfunction.
Both WT-BPIFB4 and LAV-BPIFB4 were expressed by the heart,
likely via uptake from the circulation. However, only the latter
had salutary effects on left ventricular function in diabetic mice.
Moreover, LAV-BPIFB4 prevented capillary rarefaction, fibrosis and
lipid accumulation in the diabetic heart. Reduced fibrosis may
account for the improved diastolic function. Regarding factors
influencing systolic function, we excluded an effect of LAV-BPIFB4
on cardiomyocyte hypertrophy, proliferation, or apoptosis. More-
over, LAV-BPIFB4 therapy transitorily reduced blood pressure (with-
out affecting heart rate), with this temporary effect not leading
to left ventricular mass changes. Interestingly, LAV-BPIFB4 rescued
the abundance of cardiomyocytes expressing MyHC-𝛼, improved
endothelial function, and enhanced vascular eNOS phosphoryla-
tion in diabetic mice, as seen previously in hypertensive rats.5 The
work performed by the heart during ejection is dependent upon
the inherent contractile property of individual myocytes, which
in turn is strictly related to the reciprocal expression of MyHC
isoforms.26 MyHC-𝛼 is reportedly down-regulated in the diabetic
heart20; while small amounts of MyHC-𝛼 expression are sufficient
to aid power output in cardiomyocytes.21 Therefore, induction of
the contractile protein and restoration of endothelial function may
represent pivotal drivers in the improved systolic performance we
have seen in LAV-BPIFB4-treated mice.
Controversy surrounds the benefit of cardiovascular treatments
targeting SDF-1 signalling. SDF-1 supplementation in the form of
protein, plasmid or engineered cell therapy, reportedly improved
cardiac function in mice with ischaemic cardiomyopathy.27,28 How-
ever, the STOP-HF trial, using a single endocardial administra-
tion of plasmid SDF-1 in patients with ischaemic heart failure,
failed to demonstrate its primary endpoint of improved compos-
ite score.27 Blockade of SDF-1 signalling using a CXCR4 antagonist
reduced cardiac fibrosis in diabetic rats.29 Moreover, SDF-1 has
pro-angiogenic activity,30 but is thought to exert negative inotropic



















































































.. In our study, LAV-BPIFB4, but not WT-BPIFB4 therapy, increased
SDF-1 levels in peripheral blood and heart of db/db mice. In addi-
tion, treatment of human diabetic mononuclear cells with the
LAV-BPIFB4 protein, but not WT-BPIFB4, induced intermediate
monocytes to express SDF-1. Noteworthy, myeloid cells showed
the capacity to uptake BPIFB4 in mice treated with LAV-BPIFB4
through a mechanism that remains unknown.8 Importantly, the use
of two different CXCR4 antagonists confirmed that SDF-1 sig-
nalling is involved in the therapeutic effects of LAV-BPIFB4, including
prevention of contractile dysfunction, possibly through induction of
MyHC-𝛼 and a reduction in myocardial fibrosis, microangiopathy,
and endothelial dysfunction.
In conclusion, this is the first demonstration for horizontal
transfer of a LAV gene to produce functional and anatomical
benefits on the diabetic heart (online supplementary Figure S10).
Perspectives and study limitations
The study of BPIFB4 expression in human hearts was limited to the
use of immunohistochemistry. Unavailability of frozen left ventricu-
lar material precluded the possibility to confirm the data employing
a different technique, such as western blot. Therefore, additional
studies are necessary to determine if BPIFB4 down-regulation in
the human heart contributes to the development of cardiomy-
opathies, and thereby may represent a useful diagnostic and thera-
peutic biomarker.
Additional research is also warranted to determine the modal-
ity of the BPIFB4 transgene delivery to the heart, the mecha-
nism by which LAV-BPIFB4 induces SDF-1 expression, the optimal
LAV-BPIFB4 dosage, and the need to repeat LAV-BPIFB4 gene therapy
for long-term support of the diabetic heart.
Finally, it would be interesting to ascertain if additional car-
diovascular improvements can be achieved through superim-
posing LAV-BPIFB4 gene therapy to available anti-diabetic drugs.
Non-gene-based approaches using a recombinant protein may also
be considered for clinical translation.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. Clinical characteristics of patients enrolled to the study.
Table S2. Immunofluorescence antibodies used on cardiac tissues.
Table S3. List of western blotting antibodies.
Table S4. List of flow-cytometry antibodies.
Table S5. Study 1: echocardiography indices in non-diabetic mice
given a single systemic injection of LAV-BPIFB4 or vehicle.
Table S6. Echocardiography results of first part of study 2 assess-
ing LAV-BPIFB4 vs. WT-BPIFB4 gene therapy in diabetic mice.
Table S7. Echocardiography results of second part of study 2
assessing the effect of SDF-1 antagonism on LAV-BPIFB4 gene
therapy.
Figure S1. Experimental in vivo protocols.
Figure S2. Comparison between diabetic and non-diabetic mice
at 8 and 13 weeks of age. (A) Body weight. (B,C) Bar graphs showing
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peripheral blood levels of C-peptide (B) and insulin (C). (D) FDG
uptake by the heart. (E-G) Echocardiography parameters: E/A ratio
(E), fractional shortening (F) and left ventricular ejection fraction
(G). (H) Chest hair regrowth.
Figure S3. Comparison between diabetic and non-diabetic mice at
13 weeks of age. (A) Myocyte cross-sectional area. (B) Expression
of MyHC-𝛼. (C) Western blot of the cardiac MyHC isoforms alpha
and beta. (D) Capillary density. (E,F) Interstitial (E) and perivascular
(F) fibrosis. (G) Cardiac collagen 1A1 mRNA levels. (H) Oil red
O showing lipid accumulation. (I) BPIFB4 expression. (J) Western
blot of cardiac ANP. (K) Peripheral blood immunoreactive ANP
levels.
Figure S4. (A–F) Representative immunohistochemistry images
of livers transduced with AAV9-GFP. An anti-GFP antibody (B) was
used to confirm the specificity of the green signal from GFP (A).
Merged fluorescent signals (C). A control in which the primary
antibody was omitted is shown in (D–F). (G–J) The heart of mice
injected with AAV9-GFP do not show any GFP expression (G,H).
AAV9-LAV-BPIFB4-transduced mice were used as controls (I,J).
Figure S5. Comparison between diabetic mice at 13 weeks of age.
(A) Murine Bpifb4 mRNA expression in the hearts. (B) Plasma levels
of BPIFB4.
Figure S6. Proliferation of cardiomyocytes. (A,B) Abundance
of Ki67-positive cardiomyocytes. (C) Phosphorylated histone H3
staining (nuclear green fluorescence) showing very few positive
cells expressing the marker.
Figure S7. Expression of BPIFB4, SDF-1 and cardiac MyHC-𝛼 in
hearts of three diabetic mice treated with LAV-BPIFB4.
Figure S8. Cell signalling activated by LAV-BPIFB4 and antago-
nised by AMD-070 in mice hearts. (A) Erk1/2 immunoblots. (B)
Densitometry analysis. (C) Cardiac MyHC-𝛼 and -𝛽 immunoblots.
(D) Densitometry analysis.
Figure S9. Vessels transfected with LAV-BPIFB4 are protected
from high glucose-induced endothelial dysfunction through a
CXCR4-mediated mechanism. (A) Graphs showing vasorelaxation
induced by acetylcholine. (B) Western blot for endothelial nitric
oxide synthase in the groups with or without AMD3100 treatment.
Figure S10. Translational perspective. Here, we present transla-
tional evidence for a novel salutary approach inspired by the suc-
cessful case of centenarians, who escape major age-related disease
and vertically transmit genetic protection against disease to off-
spring. Our study demonstrates that horizontal transfer of a human
longevity-associated gene variant alleviates diabetic cardiomyopa-
thy. The encoded protein could become a novel therapeutic prod-
uct to extend health-span in cardiovascular patients.
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